|Day Low/High||13.50 / 14.41|
|52 Wk Low/High||4.03 / 29.98|
There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.
In recent trading, shares of PTC Therapeutics Inc have crossed above the average analyst 12-month target price of $14.17, changing hands for $14.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
- Preliminary 2016 Translarna unaudited net sales of approximately $81M, a 140% increase vs. 2015 -
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,841 contracts have traded so far, representing approximately 384,100 underlying shares. That amounts to about 56.6% of PTCT's average daily trading volume over the past month of 678,305 shares.
Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $11.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.90.
- Award recognizes scientific innovation of first approved drug for underlying cause of nonsense mutation Duchenne muscular dystrophy -
The news that Translarna will remain on the European market for at least five more years sent PTC Therapeutics shares soaring.
--PTC to conduct a post-authorization clinical trial --
Materials, financials, cyclicals and health care names tilt the scale to the bullish side.
- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.
- Data published in the Proceedings of National Academy of Sciences (PNAS) -
Investors considering a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $10.24/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.10.
- STRIVE Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community -
Which stocks have had the highest gains following earnings? Bespoke Investment came up with a list of the 40 stocks that had the best performance on their earnings reaction days.
Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate
European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.